Company
Louisville, OS
Every investor coverage indicates participated in a round University of Louisville raised.
Companies University of Louisville acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Mark Slaughter | Professor of Surgery and Chief of the Division of Thoracic and Cardiovascular Surgery (former) | GBS Ventures (15 Jun 2010), GBS Ventures (10 Aug 2009) |
| Dr Sumanth Prabhu | Professor of Medicine and Physiology and Director of Heart Failure | GBS Ventures (10 Aug 2009), GBS Ventures (24 Nov 2008) |
Stories naming University of Louisville. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A reposted ASX announcement from Sunshine Heart reports the first minimally invasive implant of its C-Pulse heart assist system, carried out in early June by a Louisville surgeon under a US FDA feasibility trial.
Sunshine Heart announces that two female patients at Louisville's Jewish Hospital are the first US women implanted with its C-Pulse heart assist system in an FDA-approved 20-patient feasibility trial.
Medical device maker Sunshine Heart reports its first two American C-Pulse patients cleared three-month follow-ups, booked initial reimbursement revenue from an Ohio trial site, and outlines coming CE Mark and FDA steps.
Sunshine Heart says a Kentucky hospital is the first US site cleared by an ethics board to join its FDA-approved C-Pulse heart failure trial, with patient enrolment expected once contracts are signed.
Sunshine Heart won complete US regulator clearance to run its first American trial of the C-Pulse heart device, having satisfied conditions attached to September's conditional clearance; enrolment of trial participants was anticipated that year.